99久久综合狠狠综合久久,99热亚洲色精品国产88,99久久免费只有精品国产

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":37,"cheight":29,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049634500727.png","picWidth":40,"picHeight":29,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

聯系電話：0851-33411018（行政部） 0851-88173360（銷售部）股票代碼：SZ 002424

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":550,"cheight":381,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889249.png","picWidth":"550","picHeight":"381","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

貴州百靈企業集團制藥股份有限公司

股票代碼：SZ 002424

查看更多最新公告>

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":634,"cheight":56,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049634500733.png","picWidth":630,"picHeight":56,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

走進百靈

專精于藥 · 專注于人

貴州百靈企業集團制藥股份有限公司（以下簡稱“貴州百靈”）是一家從事苗藥研發、生產、銷售于一體的醫藥上市公司，注冊資本14.112億元，總資產70.59億元，員工6124人。2010年6月，公司在深圳證券交易所成功上市（股票代碼：SZ 002424）。公司明確圍繞“強化公司在苗藥領域的優勢地位，力爭成為中成藥領域具有核心競爭優勢的企業”為戰略發展目標，以實施“科技苗藥、文化苗藥、生態苗藥”為抓手，致力打造擁有大健康全產業鏈的企業集團。

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":365,"cheight":129,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"集團概況","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889219.png","picWidth":360,"picHeight":129,"inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"1","linkName":"集團概況","linkKey":"page","linkUrl":"page.html?id=675381845688348","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":363,"cheight":129,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"集團概況","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889221.png","picWidth":"373","picHeight":"129","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"1","linkName":"集團概況","linkKey":"page","linkUrl":"page.html?id=675381845688348","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":363,"cheight":129,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"藥材基地","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889220.png","picWidth":"363","picHeight":"129","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"1","linkName":"藥材基地","linkKey":"page","linkUrl":"page.html?id=675381845688358","jsonData":{}}}

致力于推動苗藥品種的科研創新

實現傳統苗藥現代化、科技化

持續挖掘和探索苗藥寶庫，以傳承

和發揚民族醫藥文化為企業使命

布局中藥材種植產業，加強道地

藥材保護，助力產業化精準扶貧

科技苗藥

文化苗藥

生態苗藥

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":754,"cheight":61,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049634500735.png","picWidth":754,"picHeight":61,"inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

產品與服務

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":754,"cheight":61,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049634500735.png","picWidth":752,"picHeight":61,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

核心產品
大健康產品

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":591,"cheight":57,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049634500734.png","picWidth":590,"picHeight":57,"inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

百靈動態

關注百靈了解更多最新資訊

百靈新聞
媒體聚焦

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":264,"cheight":161,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591153","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632202.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591153","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591153","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":272,"cheight":161,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591157","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632204.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591157","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591157","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":278,"cheight":162,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591161","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632203.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591161","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591161","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":300,"cheight":164,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591165","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632208.png","picWidth":"260","picHeight":"980","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591165","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846661591165","openType":"1","jsonData":{}}}

貴州百靈“益腎化濁顆?！雹騜期臨床試驗方案討論會順利召開

貴州百靈“黃連解毒丸”Ⅲ期臨床試驗方案討論會順利召開

貴州百靈：咳速停糖漿推動Q4業績大增，2022年凈利預增36.87%-61.02%

安順市委副書記、市長尹恒斌到貴州百靈調研復工復產工作

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":50,"cheight":20,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889230.webp","picWidth":"19","picHeight":"22","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":50,"cheight":20,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889230.webp","picWidth":"19","picHeight":"20","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":50,"cheight":22,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889230.webp","picWidth":"19","picHeight":"22","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":50,"cheight":21,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889230.webp","picWidth":"19","picHeight":"21","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

2023-02-22

2023-02-20

2023-01-31

2023-01-30

1月30日晚間，貴州百靈發布2022年業績預告。報告期內，貴州百靈預計歸屬于上市公司股東的凈利潤為1.7億元-2億元，較上年同期增長36.87%-61.02%；扣非后凈利潤為1.3億元-1.6億元，較上年同期增長53.14%-88.48%。隨著2022年12…詳細>

1月29日，安順市委副書記、市長尹恒斌到貴州百靈企業集團督導調研復工復產工作，代表市委、市政府，代表楊昌鵬書記看望慰問一線工作人員，向大家致以新春祝福和誠摯問候。市委常委、副市長顧元亮，以及安順經開區和市有關部門負責同志參加調研，貴州百靈總經理牛民…詳細>

2月18日，由貴州百靈申辦的我國首個“全科”證候類中藥新藥——黃連解毒丸Ⅲ期臨床試驗方案討論會在天津順利召開，喻示著正式開啟Ⅲ期臨床研究階段。當天會議上，來自Ⅲ期臨床組長單位天津中醫藥大學第一附屬醫院…詳細>

2月21日晚，由貴州百靈申辦、源自著名中醫腎病專家張大寧教授臨床經驗方，應用現代藥劑手段研制的中藥6類新藥——益腎化濁顆粒Ⅱb期臨床試驗方案討論會在天津順利召開。當天會議上，來自Ⅱb期臨床組長單位天津中醫藥大學第一附屬醫院...詳細>

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":272,"cheight":159,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979680","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632203.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979680","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979680","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":280,"cheight":180,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846678368269","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114148409411.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846678368269","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846678368269","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":300,"cheight":200,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979700","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114131632203.png","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979700","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979700","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":268,"cheight":163,"picBdRadio":"0","borderType":"solid","jump":"1","definedUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979709","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/1048114148409369.jpeg","picWidth":"280","picHeight":"1080","inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true,"linkData":{"linkType":"2","linkName":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979709","linkUrl":"http://www.dilettantecollection.com/displaynews.html?newsId=950846669979709","openType":"1","jsonData":{}}}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":19,"cheight":30,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889230.webp","picWidth":19,"picHeight":22,"inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

2023-01-31

2022-01-25

2023-01-15

2022-12-24

貴州百靈1月30日晚發布2022年業績預告，預計2022年歸屬于上市公司股東的凈利潤為1.7億元-2億元，同比增長36.87%-61.02%；預計扣除非經常性損益后的凈利潤為1.3億元-1.6億元，同比增長53.14%-88.48%。1月31日收盤，貴州百靈股價報收8.22元/股，漲幅為0.86%…詳細>

1月23日正月初二清晨，伴隨著鞭炮聲，貴州百靈企業集團各生產車間復工復產，1100余名員工全線到崗，鉚足干勁，以“開局就是決戰、起步就是沖刺”的精氣神，全力以赴滿足市場用藥需求、保障群眾健康生活。作為全國感冒藥、咳嗽藥、咽喉藥…詳細>

1月13日晚，貴州百靈發布公告，公司與中國中醫科學院中藥研究所簽訂《技術轉讓合同》，以2000萬元受讓“治療呼吸道病毒感染中藥1類新藥”項目。公告顯示，該藥物屬于未滿足臨床需求的國家重點研究范疇和中藥新藥申報注冊重點關注和支持的品種類別，整體技術含量高，有望成為目前全球…詳細>

12月23日晚間，貴州百靈披露公告，公司與九州通醫藥集團股份有限公司簽訂《戰略保供協議》，為進一步強化戰略合作關系，雙方就公司優先保障九州通及其下屬子公司防疫四大類產品“咳速停糖漿”的供應達成協議，協議期限自12月26日起為期一年，合作目標為5億元。該合作目標金額占…詳細>

中國證券報 | 貴州百靈：2022年凈利同比預增36.87%-61.02%

【新春走基層】貴州百靈：正月初二復工復產全力確保藥品供應鏈運轉順暢

證券日報 | 貴州百靈受讓中國中醫科學院抗病毒感染新藥技術有望填補臨床用藥空白

藍鯨財經 | 貴州百靈與九州通新簽5億元大單，保障防疫四類藥“咳速停糖漿”供應

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":751,"cheight":64,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889216.png","picWidth":751,"picHeight":64,"inpColor":"#000000","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

投資者關系

與您共享貴州百靈的發展和成績

關注我們

掃一掃關注公眾號

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":96,"cheight":98,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889260.png","picWidth":100,"picHeight":98,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":1220,"cheight":39,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"http://oss.xinghuo86.cn/666753113784399/698049642889261.webp","picWidth":1220,"picHeight":39,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

聯系我們

聯系電話：

0851-33411018（行政部）

0851-88173360（銷售部）　

地址：貴州省安順市經濟技術

開發區西航大道　

傳真：0851-33411559

走進百靈

產品與服務

新聞中心

影像百靈

投資者關系

職業發展

責任與公益

互聯網藥品信息服務資格證書編號：（黔）-非經營性—2020-0045